Filgotinib Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  ... Galapagos NVDecember 15, 2020 GMT -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majo...

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis in the U.S. Following FDA Type A Meeting — — Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 — — Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials; Gilead will Pay Galapagos €160 … — Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (...

Gilead Sciences, Inc.: Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca (Filgotinib) -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials; Gilead will Pay Galapagos €160 million to Support Ongoing Development and...

Share: -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials -- -- Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Commercial Buildout in EU -- Galapagos webcast presentation tomorrow, 16 December 2020, at 14:00 CET /...

Galapagos NV: Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca (filgotinib) -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials -- -- Gilead will Pay Galapagos €160 million to Support Ongoing Development and Acc...